LYBALVI FDA approval date
The FDA approved LYBALVI on 28 May 2021.
- FDA approval date
- 28 May 2021
- Source
- FDA record
Drug identity has not yet been verified against registry records
Also recorded as OLANZAPINE; SAMIDORPHAN L-MALATE
Included trials
No linked trials for this drug yet. Browse all trials
PDUFA dates and FDA decisions
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2021-05-28Day | LYBALVI | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213378", "applicant_as_listed_by_fda": "ALKERMES INC", "brand_names": ["LYBALVI"], "active_ingredients": ["OLANZAPINE", "SAMIDORPHAN L-MALATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210528", "matched_on": "drug record created from this FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |